Which has better earnings & valuation, LW or MED?

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lamb Weston $6.61B 1.11 $290M $2.08 25.76 Medifast $385.79M 0.35 -$18.67M -$2.33 N/A

Is LW or MED more profitable?

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Lamb Weston 4.39% 23.33% 5.72% Medifast -8.08% -6.69% -5.25%

Does the media prefer LW or MED?

In the previous week, Medifast had 1 more articles in the media than Lamb Weston. MarketBeat recorded 7 mentions for Medifast and 6 mentions for Lamb Weston. Medifast's average media sentiment score of 1.27 beat Lamb Weston's score of 1.25 indicating that Medifast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lamb Weston 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medifast 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MED or NOMD?

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.35 -$18.67M -$2.33 N/A Nomad Foods $3.43B 0.48 $154.66M $1.02 11.61

Is MED or NOMD more profitable?

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -8.08% -6.69% -5.25% Nomad Foods 4.20% 8.88% 3.53%

Does the media prefer MED or NOMD?

In the previous week, Nomad Foods had 4 more articles in the media than Medifast. MarketBeat recorded 11 mentions for Nomad Foods and 7 mentions for Medifast. Medifast's average media sentiment score of 1.27 beat Nomad Foods' score of 0.84 indicating that Medifast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nomad Foods 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MED or PRE?

In the previous week, Prenetics Global had 34 more articles in the media than Medifast. MarketBeat recorded 41 mentions for Prenetics Global and 7 mentions for Medifast. Medifast's average media sentiment score of 1.27 beat Prenetics Global's score of 0.22 indicating that Medifast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prenetics Global 5 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend YSG or MED?

Medifast has a consensus price target of $12.00, suggesting a potential upside of 0.00%. Given Medifast's stronger consensus rating and higher probable upside, analysts plainly believe Medifast is more favorable than Yatsen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yatsen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medifast 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable valuation & earnings, YSG or MED?

Yatsen has higher revenue and earnings than Medifast. Yatsen is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Yatsen $614.62M 0.46 -$11.56M -$0.21 N/A Medifast $385.79M 0.35 -$18.67M -$2.33 N/A

Is YSG or MED more profitable?

Yatsen has a net margin of -3.04% compared to Medifast's net margin of -8.08%. Yatsen's return on equity of -4.54% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Yatsen -3.04% -4.54% -3.49% Medifast -8.08% -6.69% -5.25%

Does the media refer more to MED or NATR?

In the previous week, Medifast had 2 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 7 mentions for Medifast and 5 mentions for Nature's Sunshine Products. Nature's Sunshine Products' average media sentiment score of 1.57 beat Medifast's score of 1.27 indicating that Nature's Sunshine Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nature's Sunshine Products 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Medifast (MED) Competitors

$12.00 +0.38 (+3.27%)

As of 08/21/2026 03:58 PM Eastern

Compare

MED vs. LW, NOMD, PRE, YSG, and NATR

Should you buy Medifast stock or one of its competitors? Medifast's main competitors and comparable companies include Lamb Weston (LW), Nomad Foods (NOMD), Prenetics Global (PRE), Yatsen (YSG), and Nature's Sunshine Products (NATR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "consumer staples" sector.

How does Medifast compare to Lamb Weston?

Lamb Weston (NYSE:LW) and Medifast (NYSE:MED) are both consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

89.6% of Lamb Weston shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 1.0% of Lamb Weston shares are held by insiders. Comparatively, 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lamb Weston has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Medifast has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lamb Weston	4.39%	23.33%	5.72%
Medifast	-8.08%	-6.69%	-5.25%

Lamb Weston presently has a consensus price target of $53.36, suggesting a potential downside of 0.40%. Medifast has a consensus price target of $12.00, suggesting a potential upside of 0.00%. Given Medifast's higher probable upside, analysts plainly believe Medifast is more favorable than Lamb Weston.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lamb Weston	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Medifast had 1 more articles in the media than Lamb Weston. MarketBeat recorded 7 mentions for Medifast and 6 mentions for Lamb Weston. Medifast's average media sentiment score of 1.27 beat Lamb Weston's score of 1.25 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lamb Weston	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lamb Weston	$6.61B	1.11	$290M	$2.08	25.76
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A

Summary

Lamb Weston beats Medifast on 10 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Medifast (NYSE:MED) and Nomad Foods (NYSE:NOMD) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

95.5% of Medifast shares are owned by institutional investors. Comparatively, 75.3% of Nomad Foods shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Comparatively, 17.3% of Nomad Foods shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A
Nomad Foods	$3.43B	0.48	$154.66M	$1.02	11.61

Medifast has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Nomad Foods has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Medifast presently has a consensus target price of $12.00, suggesting a potential upside of 0.00%. Nomad Foods has a consensus target price of $13.25, suggesting a potential upside of 11.91%. Given Nomad Foods' stronger consensus rating and higher possible upside, analysts plainly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Nomad Foods	4.20%	8.88%	3.53%

In the previous week, Nomad Foods had 4 more articles in the media than Medifast. MarketBeat recorded 11 mentions for Nomad Foods and 7 mentions for Medifast. Medifast's average media sentiment score of 1.27 beat Nomad Foods' score of 0.84 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nomad Foods	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nomad Foods beats Medifast on 14 of the 16 factors compared between the two stocks.

How does Medifast compare to Prenetics Global?

Medifast (NYSE:MED) and Prenetics Global (NASDAQ:PRE) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Medifast currently has a consensus target price of $12.00, suggesting a potential upside of 0.00%. Prenetics Global has a consensus target price of $34.25, suggesting a potential upside of 69.55%. Given Prenetics Global's stronger consensus rating and higher possible upside, analysts clearly believe Prenetics Global is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Medifast has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Medifast has higher revenue and earnings than Prenetics Global. Medifast is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A
Prenetics Global	$92.39M	3.69	-$37.71M	-$4.16	N/A

Medifast has a net margin of -8.08% compared to Prenetics Global's net margin of -47.43%. Medifast's return on equity of -6.69% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Prenetics Global	-47.43%	-21.41%	-15.56%

In the previous week, Prenetics Global had 34 more articles in the media than Medifast. MarketBeat recorded 41 mentions for Prenetics Global and 7 mentions for Medifast. Medifast's average media sentiment score of 1.27 beat Prenetics Global's score of 0.22 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prenetics Global	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.5% of Medifast shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Comparatively, 7.8% of Prenetics Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Medifast beats Prenetics Global on 9 of the 16 factors compared between the two stocks.

How does Medifast compare to Yatsen?

Yatsen (NYSE:YSG) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Yatsen has a beta of -1.55, indicating that its stock price is 255% less volatile than the broader market. Comparatively, Medifast has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Medifast has a consensus price target of $12.00, suggesting a potential upside of 0.00%. Given Medifast's stronger consensus rating and higher probable upside, analysts plainly believe Medifast is more favorable than Yatsen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yatsen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Yatsen has a net margin of -3.04% compared to Medifast's net margin of -8.08%. Yatsen's return on equity of -4.54% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yatsen	-3.04%	-4.54%	-3.49%
Medifast	-8.08%	-6.69%	-5.25%

In the previous week, Medifast had 7 more articles in the media than Yatsen. MarketBeat recorded 7 mentions for Medifast and 0 mentions for Yatsen. Medifast's average media sentiment score of 1.27 beat Yatsen's score of 0.00 indicating that Medifast is being referred to more favorably in the news media.

Company	Overall Sentiment
Yatsen	Neutral
Medifast	Positive

95.5% of Medifast shares are owned by institutional investors. 29.0% of Yatsen shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Yatsen has higher revenue and earnings than Medifast. Yatsen is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yatsen	$614.62M	0.46	-$11.56M	-$0.21	N/A
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A

Summary

Yatsen beats Medifast on 8 of the 15 factors compared between the two stocks.

How does Medifast compare to Nature's Sunshine Products?

Medifast (NYSE:MED) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Medifast had 2 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 7 mentions for Medifast and 5 mentions for Nature's Sunshine Products. Nature's Sunshine Products' average media sentiment score of 1.57 beat Medifast's score of 1.27 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nature's Sunshine Products	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nature's Sunshine Products has a net margin of 3.68% compared to Medifast's net margin of -8.08%. Nature's Sunshine Products' return on equity of 12.88% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Nature's Sunshine Products	3.68%	12.88%	8.17%

Nature's Sunshine Products has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A
Nature's Sunshine Products	$480.14M	0.53	$19.52M	$1.01	14.20

Medifast has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Medifast currently has a consensus price target of $12.00, indicating a potential upside of 0.00%. Nature's Sunshine Products has a consensus price target of $30.50, indicating a potential upside of 112.69%. Given Nature's Sunshine Products' stronger consensus rating and higher possible upside, analysts plainly believe Nature's Sunshine Products is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nature's Sunshine Products	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

95.5% of Medifast shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Nature's Sunshine Products beats Medifast on 13 of the 16 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	Personal Care Products Industry	Consumer Staples Sector	NYSE Exchange
Market Cap	$133.61M	$23.48B	$15.97B	$24.31B
Dividend Yield	N/A	4.29%	3.20%	3.70%
P/E Ratio	-5.15	19.22	13.58	30.31
Price / Sales	0.35	13.22	262,949.30	21.00
Price / Cash	28.79	28.69	57.57	32.49
Price / Book	0.68	2.92	4.51	6.77
Net Income	-$18.67M	$1.11B	$834.02M	$1.07B
7 Day Performance	4.90%	0.71%	0.26%	-0.65%
1 Month Performance	27.12%	2.24%	2.22%	3.38%
1 Year Performance	-15.95%	-18.64%	13.47%	14.90%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	1.9019 of 5 stars	$12.00 +3.3%	$12.00	-16.0%	$133.61M	$385.79M	N/A	870	News Coverage Negative News Insider Trade
LW Lamb Weston	3.2326 of 5 stars	$53.16 -1.2%	$53.36 +0.4%	-5.8%	$7.30B	$6.61B	25.56	10,000	Positive News
NOMD Nomad Foods	4.8118 of 5 stars	$11.73 -2.6%	$13.25 +13.0%	-24.1%	$1.64B	$3.43B	11.50	7,752	Insider Trade
PRE Prenetics Global	3.2325 of 5 stars	$19.75 +0.3%	$34.25 +73.4%	+178.6%	$333.26M	$92.39M	N/A	1	Trending News Earnings Report Analyst Upgrade Analyst Revision Gap Down
YSG Yatsen	0.4187 of 5 stars	$3.38 -0.6%	N/A	-70.7%	$318.94M	$614.62M	N/A	1,623	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, YSG, and NATR

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to Prenetics Global?

Summary

How does Medifast compare to Yatsen?

Summary

How does Medifast compare to Nature's Sunshine Products?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, YSG, and NATR

How does Medifast compare to Lamb Weston?

Do institutionals and insiders hold more shares of LW or MED?

Which has more volatility & risk, LW or MED?

Is LW or MED more profitable?

Do analysts prefer LW or MED?

Does the media prefer LW or MED?

Which has better earnings & valuation, LW or MED?

Summary

How does Medifast compare to Nomad Foods?

Do institutionals & insiders hold more shares of MED or NOMD?

Which has better valuation and earnings, MED or NOMD?

Which has more volatility & risk, MED or NOMD?

Do analysts recommend MED or NOMD?

Is MED or NOMD more profitable?

Does the media prefer MED or NOMD?

Summary

How does Medifast compare to Prenetics Global?

Do analysts recommend MED or PRE?

Which has more risk and volatility, MED or PRE?

Which has higher earnings & valuation, MED or PRE?

Is MED or PRE more profitable?

Does the media prefer MED or PRE?

Do insiders & institutionals hold more shares of MED or PRE?

Summary

How does Medifast compare to Yatsen?

Which has more risk & volatility, YSG or MED?

Do analysts recommend YSG or MED?

Is YSG or MED more profitable?

Does the media prefer YSG or MED?

Do insiders and institutionals hold more shares of YSG or MED?

Which has preferable valuation & earnings, YSG or MED?

Summary

How does Medifast compare to Nature's Sunshine Products?

Does the media refer more to MED or NATR?

Is MED or NATR more profitable?

Which has higher valuation and earnings, MED or NATR?

Which has more volatility & risk, MED or NATR?

Do analysts recommend MED or NATR?

Do institutionals & insiders believe in MED or NATR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools